Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cogent Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REPORTED POSITIVE TOP-LINE RESULTS FROM SUMMIT EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS, ACHIEVING STATISTICAL SIGNIFICANCE ACROSS ALL PRIMARY AND KEY SECONDARY ENDPOINTS ON TRACK TO SHARE PIVOTAL TRIAL RESULTS FROM PEAK IN GIST AND APEX IN ADVSM IN 2H 2025 $453 MILLION IN PRO-FORMA CASH SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED LAUNCH AND INTO 2027; INCLUDES PROCEEDS FROM UPSIZED $230 MILLION PUBLIC OFFERING IN JULY 2025 WALTHAM, MASS. AND BOULDER, COLO.

COGENT BIOSCIENCES REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2025 FINANCIAL RESULTS

WALTHAM, MASS. AND BOULDER, COLO., JULY 10, 2025 (GLOBE NEWSWIRE) -- COGENT BIOSCIENCES, INC. (NASDAQ: COGT), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING PRECISION THERAPIES FOR GENETICALLY DEFINED DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 25,555,556 SHARES OF ITS COMMON STOCK, WHICH INCLUDES 3,333,333 SHARES ISSUED PURSUANT TO THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE OFFERING. THE PUBLIC OFFERING PRICE WAS $9.00 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO COGENT FROM THIS OFFERING WERE APPROXIMATELY $230 MILLION, INCLUDING PROCEEDS FROM THE EXERCISE IN FULL BY THE UNDERWRITERS OF THE OPTION TO PURCHASE ADDITIONAL SHARES, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. ALL OF THE SHARES IN THE OFFERING WERE SOLD BY COGENT.

COGENT BIOSCIENCES ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING OF SHARES OF COMMON STOCK AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

WALTHAM, MASS. AND BOULDER, COLO., JULY 08, 2025 (GLOBE NEWSWIRE) -- COGENT BIOSCIENCES, INC.(NASDAQ: COGT), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING PRECISION THERAPIES FOR GENETICALLY DEFINED DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 22,222,223 SHARES OF ITS COMMON STOCK, OFFERED AT A PUBLIC OFFERING PRICE OF $9.00 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO COGENT FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY$200 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. IN ADDITION, COGENT HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 3,333,333 SHARES OF ITS COMMON STOCK ON THE SAME TERMS AND CONDITIONS. ALL OF THE SECURITIES IN THE OFFERING ARE BEING SOLD BY COGENT. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 10, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

COGENT BIOSCIENCES ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF SHARES OF COMMON STOCK

WALTHAM, MASS. AND BOULDER, COLO., JULY 08, 2025 (GLOBE NEWSWIRE) -- COGENT BIOSCIENCES, INC.(NASDAQ: COGT), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING PRECISION THERAPIES FOR GENETICALLY DEFINED DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF ITS SHARES OF COMMON STOCK. IN ADDITION, COGENT INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $22.5 MILLION OF ITS SHARES OF COMMON STOCK ON THE SAME TERMS AND CONDITIONS. ALL OF THE SECURITIES IN THE OFFERING ARE BEING OFFERED BY COGENT. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

COGENT BIOSCIENCES ANNOUNCES PROPOSED $150 MILLION PUBLIC OFFERING OF COMMON STOCK

-- PATIENTS TREATED WITH BEZUCLASTINIB SHOWED A SUPERIOR MEAN CHANGE IN TOTAL SYMPTOM SCORE AT 24 WEEKS (-24.3 POINTS VS. -15.4 POINTS, -8.91 POINT PLACEBO-ADJUSTED DIFFERENCE; P=0.0002), COMPARED TO PATIENTS TREATED WITH PLACEBO, ESTABLISHING NEW BENCHMARKS FOR PLACEBO-ADJUSTED AND ABSOLUTE SYMPTOMATIC IMPROVEMENT FOR THIS PATIENT POPULATION -- -- BEZUCLASTINIB DEMONSTRATED A POWERFUL EFFECT ON MAST CELL BURDEN, WITH 87.4% OF PATIENTS TREATED WITH BEZUCLASTINIB ACHIEVING AT LEAST 50% REDUCTION IN SERUM TRYPTASE COMPARED TO 0% OF PATIENTS TREATED WITH PLACEBO --

COGENT BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS ACHIEVING STATISTICAL SIGNIFICANCE ACROSS ALL PRIMARY AND KEY SECONDARY ENDPOINTS FROM THE SUMMIT TRIAL OF BEZUCLASTINIB IN PATIENTS WITH NON-ADVANCED SYSTEMIC MASTOCYTOSIS

FACILITY PROVIDES ADDITIONAL FUNDING FOR NEXT STEPS OF THE COMPANY'S GROWTH, INCLUDING THE EXPECTED LAUNCH OF BEZUCLASTINIB IN 2026 ON TRACK TO REPORT RESULTS FROM THREE PIVOTAL TRIALS THIS YEAR, BEGINNING WITH SUMMIT RESULTS IN JULY WALTHAM, MASS. AND BOULDER, COLO.

COGENT BIOSCIENCES SECURES UP TO $400 MILLION IN NON-DILUTIVE FINANCING

COGENT BIOSCIENCES ANNOUNCES PARTICIPATION IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

THREE REGISTRATION-DIRECTED TOP-LINE DATA READOUTS REMAIN ON TRACK IN 2025: SUMMIT IN NONADVANCED SM EXPECTED IN JULY, APEX IN ADVANCED SM EXPECTED IN SECOND HALF OF THE-YEAR AND PEAK IN GIST EXPECTED BY END OF YEAR ENDED 1Q 2025 WITH $245.7 MILLION IN CASH, SUFFICIENT TO FUND OPERATIONS INTO LATE 2026 WALTHAM, MASS. AND BOULDER, COLO.

COGENT BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

COGENT BIOSCIENCES PRESENTS FOUR POSTERS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2025 AND ANNOUNCES TWO NEW LEADERS

FOUR ABSTRACTS ACCEPTED FOR POSTER PRESENTATION HIGHLIGHT COGENT'S EXPERTISE IN PIONEERING BEST-IN-CLASS THERAPEUTICS FOUR ABSTRACTS ACCEPTED FOR POSTER PRESENTATION HIGHLIGHT COGENT'S EXPERTISE IN PIONEERING BEST-IN-CLASS THERAPEUTICS

Cogent Biosciences, Inc.

COGT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cogent Biosciences, Inc.

COGT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

COGT